Recent Updates

July 2019

GlucoRx CarePoint pen needles 4mm/31G, 5mm/31G, and 6mm/31G have been added to the formulary as green (first line) products for insulin delivery pen devices; GlucoRX FinePoint and BD Viva pen needles have been reclassified as blue (second line). Click here for more information.

  • Microdot droplet needles (all sizes) and Omnican Fine needles (31G sizes) have been removed

Desmopressin oral lyophilisates 25micrograms & 50micrograms have been added to the formulary as an amber (specialist) option for primary idiopathic nocturnal polyuria in adults; doses are gender specific. Click here for more information.

  • Desmopressin tablets 100micrograms, 200micrograms, oral lyophilisates 120micrograms, 240micrograms, and nasal spray 10micrograms have been reclassified as amber (specialist) drugs

UrgoStart Plus Pad 6cm x 6cm, 10cm x 10cm, 15cm x 20cm have been added to the formulary as an amber (specialist) option for diabetic foot ulcers. Click here for more information

  • UrgoStart Non-Adhesive 12cm x 19cm (heel) dressings have been removed

Secondary prevention of stroke / TIA in primary care: Formulary guidance has been reviewed and updated. Please see the formulary entry for further guidance.

Gender dysphoria and transgender prescribing: Interim guidance which summarises the prescribing responsibilities described by NHS England, and advice for GPs regarding requests by private online medical service providers has been added to the formulary. Please see the formulary for further information and links to useful resources.

Consideration given to: NHS England has published updated guidance for CCGs on items which should not be routinely prescribed in primary care. Click here for more information. New guidance has been added for the following items:

The Modafinil Specialised Medicines Service (SMS) prescribing guideline is now Devon-wide, the formulary entry has been updated to reflect this. The guideline can be found here

May 2019

Foodlink Complete with Fibre powder sachets have been added to the formulary as an amber (specialist) option for patients who require an enhanced fibre oral nutritional supplement. Click here for more information.

  • AYMES Shake sachets have been removed

Dermatonics® Once Heel Balm (25% urea) has been added to the formulary as an amber (specialist) option for the treatment of callused, anhidrotic, fissured, and hard foot skin conditions. Click here for more information.

Flexitol® 25% Urea Heel Balm has been added to the formulary as an amber (specialist) option for the treatment of callused, anhidrotic, fissured, and hard foot skin conditions. Click here for more information.

Ganciclovir 0.15% w/w eye gel has been added to the formulary as an amber (specialist) option for acute herpetic keratitis (dendritic and geographic ulcers). Click here for more information.

  • Aciclovir 3% w/w eye ointment has been removed, following discontinuation from the worldwide market by the manufacturer.

Commissioning Policy: The routine commissioning of semaglutide is accepted in Devon for patients with type 2 diabetes as described for glucagon-like peptide-1 (GLP-1) mimetics in NICE guideline NG28 (see Commissioning Policy for more details). Semaglutide has been added in the formulary as a green (first line) option in line with the policy. Click here for more information

Commissioning Policy: The routine commissioning of FreeStyle Libre is accepted in Devon for patients with diabetes mellitus in line with specific criteria (see Commissioning Policy for more details). Click here for more information.

March 2019

Cilique (ethinylestradiol 35micrograms/ norgestimate 250micrograms) tablets have been added to the formulary as a green (first line) option for hormonal contraception. Click here for more information.

  • Cilest (ethinylestradiol 35micrograms/ norgestimate 250micrograms) tablets have been discontinued by the manufacturer and have been removed from the formulary

Cilodex (ciprofloxacin 3mg/ml & dexamethasone 1mg/ml) ear drops, suspension has been added to formulary as a blue (second line) option for acute otitis externa (AOE) in adults and children over 1 year of age. Click here for more information.

DEKAs Plus (liquid, chewable tablets, and softgels) and DEKAs Essential capsules have been added to the formulary as amber (specialist input) options for the dietary management of cystic fibrosis patients. Click here for more information.

Paravit-CF liquid has been added to the formulary as amber (specialist input) options for the dietary management of cystic fibrosis in babies and patients with swallowing difficulties. Click here for more information.

Lyme disease: Formulary guidance has been revised and updated. The updated guidance provides more detail including specific antibiotic recommendations depending on the patient's age and presenting symptoms. Please see the formulary for further guidance.

Management of gout: Formulary guidance has been revised and updated. Please see the formulary for further guidance.

Dexamfetamine drug entry has been updated to support and guide prescribers on the safe and effective use of the medication. Please see the formulary for further guidance.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital